Private-public alliance for the common good
Merck gets funding from GAVI to produce Ebola vaccine
Published in Microbiology
Like
Be the first to like this
A private-public deal will fund Merck&Co to produce, stockpile and attain approval for an Ebola vaccine that showed promising results last year, Nature and Science report. GAVI, a swiss organization that helps poor countries vaccinate children, announced yesterday at the World Economic Forum in Davos, Switzerland, that it will provide US $5 million to make this possible.
This vaccine is currently being used to vaccinate all known contacts of the recent Sierra Leone Ebola victim.
Follow the Topic
Microbiology
Life Sciences > Biological Sciences > Microbiology
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in